Geron Corporation (NASDAQ:GERN) Receives Consensus Rating of “Hold” from Analysts

Geron Corporation (NASDAQ:GERN) has been assigned an average recommendation of “Hold” from the six analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $2.50.

Separately, Weiss Ratings downgraded shares of Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd.

Institutional Trading of Geron

A number of institutional investors have recently bought and sold shares of the business. 55 North Private Wealth LLC acquired a new position in shares of Geron during the 4th quarter worth approximately $29,000. Hsbc Holdings PLC acquired a new stake in shares of Geron in the first quarter valued at approximately $33,000. LCM Capital Management Inc raised its position in shares of Geron by 80.6% in the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC bought a new stake in shares of Geron in the fourth quarter valued at approximately $33,000. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of Geron by 3,307.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 24,410 shares during the period. Institutional investors own 73.71% of the company’s stock.

Geron Stock Performance

GERN opened at $1.36 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.78 and a quick ratio of 4.96. The business has a fifty day simple moving average of $1.31 and a 200 day simple moving average of $1.45. Geron has a 1 year low of $1.04 and a 1 year high of $2.01. The company has a market capitalization of $872.47 million, a PE ratio of -12.36 and a beta of 0.60.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.The firm had revenue of $51.84 million for the quarter, compared to analysts’ expectations of $50.59 million. Research analysts expect that Geron will post -0.02 EPS for the current year.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.